Letrozol Glenmark (Letrozole)

Letrozol Glenmark is an aromatase inhibitor indicated for hormone‑driven breast cancer conditions.

• Postmenopausal estrogen receptor‑positive breast cancer: reduces tumor growth by decreasing estrogen synthesis.
• Adjuvant therapy for early‑stage hormone‑receptor‑positive breast cancer: lowers risk of disease recurrence.
• Advanced or metastatic breast cancer in postmenopausal women: helps control disease progression.

• Letrozole reversibly binds to the aromatase enzyme, inhibiting its activity. By blocking aromatase, the conversion of androgens to estrogens is reduced, leading to markedly lower circulating estrogen levels. This estrogen depletion limits the growth stimulus for estrogen‑dependent breast cancer cells, thereby exerting an antineoplastic effect.

Letrozol Glenmark may cause a range of adverse reactions, which vary in frequency and severity.

Common Side Effects

• Hot flashes: sudden feeling of warmth, often with sweating.
• Joint and muscle pain: aching or stiffness in joints or muscles.
• Fatigue: persistent tiredness not relieved by rest.
• Nausea: feeling of queasiness or urge to vomit.
• Headache: mild to moderate head pain.
• Dizziness: sensation of light‑headedness or unsteadiness.

Serious or Rare Side Effects

• Severe liver injury: jaundice, dark urine, or elevated liver enzymes.
• Bone fracture: increased risk due to reduced bone mineral density.
• Pulmonary embolism: sudden shortness of breath, chest pain.
• Deep vein thrombosis: swelling, pain in a leg.
• Allergic reactions: rash, itching, swelling, or anaphylaxis.
• Cardiac arrhythmia: abnormal heart rhythm, including QT prolongation.

Before initiating Letrozol Glenmark, clinicians should consider several safety measures.

• Bone health monitoring: assess baseline bone density and consider calcium/vitamin D supplementation.
• Liver function assessment: obtain baseline liver enzymes and monitor periodically.
• Cardiovascular risk evaluation: review history of thromboembolic events or heart disease.
• Hypersensitivity screening: avoid use in patients with known allergy to letrozole or excipients.
• Store at ambient temperature: keep below 25°C, in the original packaging, protected from moisture.

Letrozol Glenmark can interact with other medicines, affecting its efficacy or safety.

Major Interactions (Avoid)

• Estrogen replacement therapy: antagonizes letrozole’s estrogen‑lowering effect.
• Strong CYP2A6 inhibitors (e.g., fluvoxamine): may increase letrozole plasma concentrations.
• Concurrent use with tamoxifen: opposing mechanisms may reduce therapeutic benefit.

Moderate Interactions (Monitor Closely)

• CYP3A4 inducers (e.g., rifampin, carbamazepine): may lower letrozole levels, reducing efficacy.
• Warfarin: letrozole may enhance anticoagulant effect, requiring INR monitoring.
• Selective serotonin reuptake inhibitors (SSRIs): potential modest impact on metabolism; observe for altered response.